On October 29, METIS TECHBIO-P rose 5.07% in regular trading, with the shares trading at HK$12.03 and turnover at HK$23.16 million.
The clearest recent catalyst remains the company’s strategic collaboration with Eli Lilly on next-generation tissue-specific LNP delivery technology, a theme that continued to be highlighted in the latest market coverage on October 28.
Under the disclosed terms, METIS TECHBIO-P is eligible to receive an upfront payment in the low double-digit millions of U.S. dollars, up to about US$1.1 billion in development, regulatory and commercial milestone payments, and potential single-digit tiered royalties. The collaboration uses its AI-driven AiLNP platform and NanoForge infrastructure, while Lilly contributes drug discovery, development and commercialization capabilities. Recent market commentary indicated that the deal further validates the platform’s differentiated value and may support continued recognition of its commercial potential.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments